International Human Insulin Market Overview, Trends & Forecast to 2018

Press Release   •   Sep 24, 2014 07:34 EDT

RNR presents analysis and discussion about human insulin market, its forecasts and more is now available in the global research report “Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018”. This report can be ordered at ReportsnReports.com.

Several initiatives and healthcare reforms have been developed in order to support the adoption of human insulin among diabetic population as diabetes will be the seventh leading cause of mortality by 2030. WHO and IDF began joint initiative to reduce the impact of diabetes and related chronic conditions on the health of children and adults worldwide. Apart from this, the U.S. government has now started taking various initiatives to boost its biosimilars market. In 2013, Obama’s administration sponsored a budget of $4.5 billion, an increase of 17% over 2012, to FDA in order to support the review of generics and biosimilars. The funding would mostly come from user fees paid by drug makers. More than $364 million will be allocated to support generic drug activities and development of biosimilars, out of which $20 million will be allocated to the FDA for biosimilars.

Modern human insulin accounted for the largest share -84%- of global human insulin market. Premixed modern human insulin and long acting human insulin are estimated to grow at a brisk pace over the next five years. The high growth in these segments can be attributed to the growing demand of Apidra, Lantus, and Levemir. Furthermore, these drugs reported high efficiency and effectiveness as compared to other synthetic insulin, animal insulin, and other human insulin.

New technologies such as safety pen needles and infusion pumps have emerged as efficient mode of delivery for human insulin. Pen needles offer significant benefits to the healthcare sector. The usage of easy to fit needles is rising due to the convenience offered by them. These needles are easy to attach, remove, and dispose, thus they can be easily used by patients with manual dexterity problems, and visual impairment. Diabetes educators and clinicians across the world recommend the usage of needles with shorter lengths and higher gauge sizes for convenience and to minimize pain. Owing to these factors, technological advancement is expected to be a major revenue pocket for the human insulin market in the coming years.

Countries such as China, India, Japan, and Korea will also offer potential growth opportunities to human insulin market. Of all the countries, China is estimated to be the fastest growing market for human insulin market. Saudi Arabia, Qatar, Egypt, U.A.E, and Brazil will also emerge as lucrative markets for human insulin market.

Complete report available at http://www.reportsnreports.com/reports/291200-human-insulin-market-by-product-type-human-insulin-short-acting-intermediate-acting-premixed-modern-human-insulin-rapid-acting-long-acting-premixed-by-brand-lantus-apidra-levemir-novorapid-novomix-tresiba-others-forecast-to-2018.html .

Above all, most of the early biologic human insulin lost their patent protection in the first half of the 20th century, while many of the current best-selling drugs such as insulin glargine, insulin as part, and insulin lispro are all set to lose their patent protection in the coming years. This creates new opportunities for biosimilar drugs which is estimated to grow at a CAGR of 35% from 2014-2019.

The grey area while estimating the market size is the variable price of human insulin across the globe as it differs widely across each country.

From an insight perspective, this research report focuses on the qualitative data, market size, share, and growth of various segments and sub-segments, competitive landscape, and company profiles.

The qualitative data covers various levels of industry analysis, such as market dynamics (drivers, restraints, opportunities, and threats), and porter’s five forces analysis at global level. The report also offers market shares, sizes, and related growth of various segments in the industry. It also focuses on the emerging and high-growth segments of human insulin market (Biosimilars of human insulin, long acting human insulin, and premixed human insulin), high-growth regions (Asia-Pacific), and the initiatives of their respective governments.

The competitive landscape covers the growth strategies adopted by industry players in the last three years. The company profiles comprise the basic views on the key players in the human insulin market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Inquire for discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=291200 . (Original Price US $4650 for single user)

Table of Contents

1 Introduction

2 Executive Summary

3 Premium Insights

4 Market Overview

5 Human Insulin Market, By Types

6 Human Insulin Market, By Brand

7 Human Insulin Market, By Geography

8 Competitive Landscape

9 Company Profiles

List Of Figures

Figure 1 Research Methodology

Figure 2 Market Size Estimation Methodology

Figure 3 Data Triangulation Methodology

Figure 4 Biologic Vs. Biosimilar Human Insulin: Market Size forecast, 2011–2018

Figure 5 Human Insulin Market, Traditional Vs. Modern Human Insulin,2014-2019 ($Million)

Figure 6 Human Insulin Market, Biologics Vs. Biosimilar,2014-2019 ($Million)

Figure 7 Human Insulin Market, By Brands,2014-2019 ($Million

Figure 8 Human Insulin Market,Sub Segment of Biopharmaceutical Market

Figure 9 Human Insulin Market Snapshot,2013($Million)

Figure 10 Human Analysis Market,Geographic Analysis,By Product,2013($Million)

Figure 11 Market Dynamics : Human Insulin Market

Figure 12 Opportunity Matrix: Global Human Insulin Market, By Brands,2013

Figure 13 Human Insulin Timeline

Figure 14 Human Insulin,Market Segmentation

Figure 15 Market Share Analysis, By Key Players

Figure 16 Prther's Five force Analysis

Figure 17 Major Potential Market

Figure 18 Modern Human Insulin Market, By Types, 2014 Vs 2019 ($Million

Figure 19 Traditional Human Insulin Market, By Brand, 2014 Vs2019 ($Million

Figure 20 Modern Human Insulin Market, By Brand, 2014 Vs 2019 ($Million

Figure 21 Opportunity Matrix; Human Insulin Market , By Geography ,2014

Figure 22 Opportunity Matrix : Human Insulin Market, By Country ,2014

Figure 23 Key Growth Strategies, 2011-2014

Figure 24 Novo Nordisk: Geographic Presence (Manufacturing Unit)

Figure 25 Novo Nordisk: Financials, 2011-2013($Million)

Figure 26 Novo Nordisk: Buisness Revenue Mix,2013,($Million)

Figure 27 Novo Nordisk: Geographic Revenue Mix,2013,($Million)

Figure 28 Eli Lilly: Geographic Presence (Manufacturing Unit)

Figure 29 Eli Lilly: Financials, 2011-2013($Million)

Figure 30 Eli Lilly: Buisness Revenue Mix,2013,($Million)

Figure 31 Eli Lilly: Geographic Revenue Mix,2013,($Million)

Figure 32 Sanofi Aventis : Geographic Presence (Manufacturing Unit)

Figure 33 Sanofi Aventis: Financials, 2011-2013($Million)

Figure 34 Sanofi Aventis: Buisness Revenue Mix,2013,($Million)

Figure 35 Sanofi Aventis: Geographic Revenue Mix,2013,($Million)

Figure 36 Biocon : Geographic Presence (Manufacturing Unit)

Figure 37 Biocon: Financials, 2011-2013($Million)

Figure 38 Biocon: Buisness Revenue Mix,2013,($Million)

Figure 39 Biocon: Geographic Revenue Mix,2013,($Million)

Figure 40 Julphar Pharmaceuticals : Geographic Presence (Manufacturing Unit)

Figure 41 Julphar Pharmaceuticals: Financials, 2011-2013($Million)

Figure 42 Julphar Pharmaceuticals: Buisness Revenue Mix,2013,($Million)

Figure 43 Julphar Pharmaceuticals: Geographic Revenue Mix,2013,($Million)

Purchase a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=291200 . (This is a premium research report priced at US$ 4650 for single user PDF license).

About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. This comprehensive collection of market research reports include market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more. Our research specialists & industry experts, through our market research offerings, ensure we deliver on all your business & industry research requirements - first time and every time!